BrainsWay Ltd. (BWAY)

Market Cap	646.59M +305.6%
Revenue (ttm)	52.23M +27.3%
Net Income	7.58M +159.3%
EPS	0.18 +229.1%
Shares Out	40.03M
PE Ratio	85.36
Forward PE	43.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	368,788
Open	16.63
Previous Close	16.74
Day's Range	15.35 - 16.81
52-Week Range	4.60 - 17.35
Beta	0.22
Analysts	Strong Buy
Price Target	13.25 (-18.76%)
Earnings Date	May 13, 2026

About BWAY

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 17, 2019
• Employees: 129
• Stock Exchange: NASDAQ
• Ticker Symbol: BWAY
• Website: https://www.brainsway.com

Financial Performance

In 2025, BrainsWay's revenue was $52.23 million, an increase of 27.33% compared to the previous year's $41.02 million. Earnings were $7.58 million, an increase of 159.33%.

Analyst Summary

According to 2 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price target is $13.25, which is a decrease of -18.76% from the latest price.

Price Target

$13.25

(-18.76% downside)

Analyst Consensus: Strong Buy